IMMUCELL CORP quarterly report, Q1 FY2012

Business context and reporting period

ImmuCell Corporation filed this unaudited Form 10-Q for the quarter ended March 31, 2012. The company develops, manufactures and sells products for dairy and beef animal health. Its principal commercial product is First Defense; Mast Out, an investigational mastitis treatment, remains subject to development and regulatory approval.

Financial performance and liquidity

Sales increased about 10%, while gross margin dollars rose about 17%. Management attributed the return to quarterly profitability principally to higher First Defense gross margin and reduced product-development spending. Product-development expense fell to $248,000 from $472,000, primarily because Mast Out spending was lower at this stage. Sales and marketing expense increased to $241,000 from $204,000.

At March 31, cash and cash equivalents were $1.571 million and short-term investments were $3.483 million, totaling $5.054 million, up $94,000 from year-end. Working capital was $6.780 million. Total assets were $11.171 million and stockholders’ equity was $9.247 million. Bank debt was approximately $1.398 million, including $175,000 current and $1.223 million long-term; the facilities are secured by substantially all company assets. The company reported compliance with debt covenants and a covenant requirement to maintain at least $1 million of unrestricted cash, cash equivalents and short-term investments. It stated that resources were sufficient for working capital and operations for at least the next 12 months.

Operating cash flow was lower year over year despite positive earnings, including because receivables increased. Capital expenditures were $112,000. Cash rose by $790,000, with investing cash flow benefiting from net investment maturities and financing cash flow including $51,000 from option exercises and $42,000 of debt repayments.

Material changes versus the prior comparable period

• Product sales grew approximately 10%; domestic sales increased 8% and international sales 19%. First Defense sales increased 13% year over year in the quarter, according to management.
• Wipe Out Dairy Wipes sales declined 10% in the quarter; management cited price competition and a shrinking customer segment.
• Operating results improved from a small operating loss to $281,000 operating income, and net results moved from a $23,000 loss to $155,000 income.
• Administrative expense increased 16% to $242,000. Management cited public-company compliance costs.
• The cash-flow comparison was affected by investment activity: Q1 2012 had $583,000 net investing inflow, versus $1.325 million net investing outflow in Q1 2011.

Outlook, commentary and risks

• Management described First Defense sales growth as sustained and attributed some of it to increased sales and marketing efforts, including collaboration with AgriLabs. It cautioned that seasonality and mild, dry spring weather could affect demand, and that distributor inventory could weigh on second-quarter sales.
• The company estimated approximately $13 million would be needed to complete Mast Out development and bring it to market. It was seeking partner funding, debt and other incentives; prospective partners were conducting due diligence, but no agreement was assured. Management said discussions were taking longer than desired.
• Mast Out requires FDA approval. The filing reported an FDA complete letter for the Target Animal Safety section during Q2 2012; the Effectiveness section remained under FDA review after a resubmission, with a response expected in Q2. The company anticipated completing additional Human Food Safety work in Q3 2012 and submitting the Chemistry, Manufacturing and Controls section in Q2, with review comments expected by year-end. The filing identifies CMC approval as a critical path to the administrative application and potential sales.
• Management was seeking amendments to Lonza manufacturing terms or considering self-sourcing the active ingredient; either route involved investment, and a new facility could delay launch. FDA approval, partner funding, manufacturing costs and timing remained uncertain.
• Key risks include reliance on First Defense sales, dairy-industry economics and input costs, customer and distributor concentration, raw-material and manufacturing dependencies, product-development and regulatory uncertainty, and Mast Out market acceptance. Two customers accounted for 54% of Q1 sales (40% and 14%).
• The company reported no legal proceedings and no quantitative or qualitative market-risk disclosures. Management concluded disclosure controls were effective and reported no material quarterly change in internal control over financial reporting.

Important facts for investors to verify

1. Whether First Defense sales growth and gross margins persist, and whether distributor inventories affect subsequent-quarter orders.
2. Progress, timing and costs for Mast Out FDA reviews, including the status of the Effectiveness and CMC sections and the required Human Food Safety work.
3. Whether ImmuCell secures acceptable partner or other financing for the estimated $13 million Mast Out completion and launch investment.
4. Debt-covenant compliance, the $1 million minimum liquidity requirement, and the sufficiency of available funds as development and capital needs evolve.
5. Exposure to major distributors: Animal Health International and MWI represented 40% and 14% of quarterly sales, respectively; confirm customer concentration and receivable collection trends.